Sanofi
HealthcareNASDAQ:SNY · NASDAQ Global Select
+$0.18 today
Vol 1.17M · Avg 2.81M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$47.4B of revenue converted into $7.6B of net income for the selected period. Gross margin is 72.1% and net margin is 16.4%, showing how much revenue survives after costs and taxes. EPS is $1.95, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $46.7B +5.5% | $44.3B +6.4% | $41.6B +2.6% | $40.6B +3.5% | $39.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $13.0B -1.2% | $13.2B +4.6% | $12.6B +6.3% | $11.9B -3.0% | $12.3B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $33.7B +8.3% | $31.1B +7.2% | $29.0B +1.1% | $28.7B +6.5% | $26.9B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 72.1% +1.9pp | 70.2% +0.5pp | 69.7% -1.0pp | 70.7% +2.0pp | 68.7% | 9.8% | 28.9% | 38.3% |
| Research & Development | $7.8B +6.1% | $7.4B +13.6% | $6.5B +0.1% | $6.5B +14.2% | $5.7B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $10.2B +11.5% | $9.2B +2.8% | $8.9B +2.2% | $8.7B -8.5% | $9.6B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $24.1B +1.0% | $23.8B +8.2% | $22.0B +19.0% | $18.5B -1.5% | $18.8B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $5.7B +58.3% | $3.6B -19.0% | $4.4B +42.5% | $3.1B -7.3% | $3.4B | $374.2M | $1.2B | $631.8M |
| EBITDA | $12.5B +13.1% | $11.0B -3.1% | $11.4B -15.7% | $13.5B +17.1% | $11.5B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 26.7% +1.8pp | 24.9% -2.5pp | 27.4% -5.9pp | 33.3% +3.9pp | 29.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $9.6B +32.3% | $7.3B +4.2% | $7.0B -31.5% | $10.2B +25.1% | $8.1B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 20.5% +4.2pp | 16.4% -0.3pp | 16.7% -8.3pp | 25.1% +4.3pp | 20.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $331.0M -27.7% | $457.5M -13.8% | $530.5M +214.0% | $169.0M +5303.2% | $3.1M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $626.0M +0.6% | $622.6M +21.4% | $512.8M +33.3% | $384.8M +2.0% | $377.4M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$3.6B -624.1% | -$494.0M +41.5% | -$845.0M -397.1% | -$170.0M +41.2% | -$289.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $6.0B -10.9% | $6.8B +10.5% | $6.1B -38.8% | $10.0B +27.5% | $7.8B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 12.9% -2.4pp | 15.3% +0.6pp | 14.7% -9.9pp | 24.6% +4.6pp | 20.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.0B -13.4% | $1.2B +18.4% | $1.0B -46.7% | $1.9B +22.5% | $1.6B | $1.3B | -$1.6B | $745.2M |
| Net Income | $7.8B +40.5% | $5.6B +3.0% | $5.4B -35.5% | $8.4B +34.5% | $6.2B | $4.9B | $4.8B | $4.7B |
| Net Margin | 16.7% +4.2pp | 12.6% -0.4pp | 13.0% -7.7pp | 20.6% +4.8pp | 15.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 +46.1% | $2 +1.9% | $2 -32.6% | $3 +28.1% | $2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 +46.1% | $2 +1.9% | $2 -32.4% | $3 +27.7% | $2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $2.4B -2.5% | $2.5B -0.0% | $2.5B -0.0% | $2.5B -0.0% | $2.5B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $2.4B -2.5% | $2.5B -0.4% | $2.5B +0.4% | $2.5B -0.0% | $2.5B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Amgen Inc.
NASDAQ:AMGN
$190.74B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.36B
Pfizer Inc.
NYSE:PFE
$149.07B
CVS Health Corporation
NYSE:CVS
$129.95B
Bristol-Myers Squibb Company
NYSE:BMY
$116.55B
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
$112.69B
GSK plc
NYSE:GSK
$106.55B
Medtronic plc
NYSE:MDT
$103.10B
HCA Healthcare, Inc.
NYSE:HCA
$85.76B
Bristol-Myers Squibb Company Ce
CELG-RI
$250.97M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SNY generate?
Sanofi (SNY) reported $46.72B of revenue in fiscal 2025.
Is SNY profitable?
Sanofi (SNY) reported $7.81B of net income, with a net margin of 16.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.